【摘要】 目的 探讨阿帕替尼治疗多线化疗后复发小细胞肺癌（SCLC）患者的效果。方法 选取本院收治的100例多线化疗后复发的SCLC患者，以随机数字表法将其分为对照组和观察组，各50例。对照组以EP（顺铂+依托泊苷）化疗方案治疗，观察组在对照组基础上增加阿帕替尼治疗。比较两组的临床疗效。结果 观察组的客观缓解率（ORR）、疾病控制率（DCR）高于对照组（P<0.05）。治疗后，观察组的癌胚抗原（CEA）、糖链抗原19-9（CA19-9）、糖链抗原50（CA50）、血管内皮生长因子（VEGF）、胰岛素样生长因子-1（IGF-1）、转化生长因子-β₁（TGF-β₁）水平低于对照组（P<0.05）。两组的不良反应总发生率无显著差异（P>0.05）。结论 阿帕替尼治疗多线化疗后复发SCLC患者的效果显著。更多还原

【Abstract】 Objective To analyze the effect of apatinib in the treatment of patients with recurrent small cell lung cancer（SCLC） after multiline chemotherapy. Methods A total of 100 patients with recurrent SCLC after multiline chemotherapy admitted in our hospital were selected and divided into control group and observation group by random number table method,with 50 cases in each group. The control group was treated with EP（cisplatin + etoposide） chemotherapy, and the observation group was treated with apatinib on the basis of the control group. The clinical efficacy of the two groups was compared. Results The objective response rate（ORR） and disease control rate（DCR） of the observation group were higher than those of the control group（P<0.05）. After treatment, the levels of carcinoembryonic antigen（CEA）, carbohydrate antigen 19-9（CA19-9）,carbohydrate antigen 50（CA50）, vascular endothelial growth factor（VEGF）, insulin-like growth factor-1（IGF-1） and transforming growth factor-β₁（TGF-β₁） in the observation group were lower than those in the control group（P<0.05）. There was no significant difference in the total incidence of adverse reactions between the two groups（P>0.05）. Conclusion Apatinib has significant effect in the treatment of patients with recurrent SCLC after multiline chemotherapy.更多还原